EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immunohistochemical characteristics and potential therapeutic regimens of hepatoid adenocarcinoma of the stomach: a study of 139 cases

Xuesong Yang iD, Yan Wu, Anqiang Wang, Xiuli Ma, Kai Zhou, Ke Ji, Xin Ji, Ji Zhang, Xiaojiang Wu, ZhongWu Li, Zhaode Bu

The Journal of Pathology: Clinical Research · 2024

DOI: 10.1002/cjp2.343 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pathology: Clinical Research, 2024. Verfasst von Xuesong Yang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Center of Gastrointestinal Cancer, Peking University Can…. Hauptthemen laut MEDLINE: Epstein-Barr Virus Infections, Adenocarcinoma, Stomach Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Hospital Authority Clinical Medicine Development of Special Funding Support, Capital's Funds For Health Improvement and Research (No. CFH 2022-4-1025), Beijing Youth Talent Plan, Science Foundation of Peking University Cancer Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatoid adenocarcinoma of stomach (HAS) is a special subtype of gastric cancer with poor prognosis. Immunohistochemical analysis could provide important clues for the treatment of HAS. A total of 159 patients were diagnosed as HAS and 139 were enrolled in this study. Statistical differences were determined using relative test methods and survival analyses were performed by the Kaplan–Meier method to find survival differences. All tumors in this study were negative for Epstein–Barr virus‐encoded small RNAs (EBERs) and almost all showed no loss of mismatch repair (MMR) proteins and were positive for alpha fetoprotein (AFP or spalt like transcription factor 4 (SALL4). About half of the tumors had a positive programmed death‐ligand 1 combined positive score (CPS) and 17.3% were positive for human epidermal growth factor receptor 2 (HER2). In addition, there was a relatively high proportion of cmet expression. We also found that HAS patients with recurrent disease treated by emerging therapy had a better survival than those treated with traditional chemotherapy ( p = 0.002, median recurrence‐to‐death survival: 23 months versus 6 months); HAS patients who received anti‐HER2 therapy or harbored MMR deficiency had favorable prognosis. Overall, high proportions of MMR protein proficiency, positivity for AFP or SALL4, overexpression of HER2, CPS and cmet, as well as negative EBER findings, are distinctive characteristics of HAS patients. While negative EBER and MMR proficiency indicate molecular features of HAS, positivity for AFP or SALL4 could aid in the diagnosis of HAS. In addition, HAS patients could benefit from anti‐HER2 therapy, immunotherapy, and anti‐angiogenesis therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epstein-Barr Virus InfectionsAdenocarcinomaStomach NeoplasmsHumansalpha-FetoproteinsBiomarkers, TumorHerpesvirus 4, Human

Stichwörter der Autor:innen

hepatoid adenocarcinoma of stomachimmunohistochemistrytargeted therapy

Substanzen

alpha-FetoproteinsBiomarkers, Tumor

Autor:innen und Institutionen

  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Center of Gastrointestinal Cancer, Peking University Cancer Hospital & Institute, Beijing, PR China.
  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Pathology, Peking University Cancer Hospital & Institute, Beijing, PR China.

ORCID-Profile: Xuesong Yang

Förderung

  • Beijing Hospital Authority Clinical Medicine Development of Special Funding Support
  • Capital's Funds For Health Improvement and Research (No. CFH 2022-4-1025), Beijing Youth Talent Plan
  • Science Foundation of Peking University Cancer Hospital

Zitieren

APA

Yang, X., Wu, Y., Wang, A., Ma, X., Zhou, K., Ji, K., Ji, X., Zhang, J., Wu, X., Li, Z., & Bu, Z. (2024). Immunohistochemical characteristics and potential therapeutic regimens of hepatoid adenocarcinoma of the stomach: a study of 139 cases. The Journal of Pathology: Clinical Research. https://doi.org/10.1002/cjp2.343

Vancouver

Yang X, Wu Y, Wang A, Ma X, Zhou K, Ji K, et al. Immunohistochemical characteristics and potential therapeutic regimens of hepatoid adenocarcinoma of the stomach: a study of 139 cases. The Journal of Pathology: Clinical Research. 2024. doi:10.1002/cjp2.343

BibTeX
@article{Yang2024,
  author = {Yang, Xuesong and Wu, Yan and Wang, Anqiang and Ma, Xiuli and Zhou, Kai and Ji, Ke and Ji, Xin and Zhang, Ji and Wu, Xiaojiang and Li, ZhongWu and Bu, Zhaode},
  title = {Immunohistochemical characteristics and potential therapeutic regimens of hepatoid adenocarcinoma of the stomach: a study of 139 cases},
  journal = {The Journal of Pathology: Clinical Research},
  year = {2024},
  doi = {10.1002/cjp2.343}
}
Kostenlos starten →